OSAKA -- Osaka University and drugmaker Nobelpharma will conduct first-round clinical trials of a promising malaria vaccine developed by the school in West Africa starting in May.
A total of 153 people will take part in the tests in Burkina Faso -- adults, children between the ages of 5 and 10, and 1-year-old infants. The individuals will be divided into two groups, one given the experimental vaccine, the other an existing tetanus vaccine. The safety of the candidate vaccine will be determined by monitoring the health of the subjects.
